Effect of Glucagon and Glucagon-like Peptide-1 Co-agonism on Cardiac Function and Metabolism in Overweight Participants With Type 2 Diabetes

Conditions:   Type2 Diabetes;   Obesity Interventions:   Drug: 0.9% Sodium-chloride;   Drug: Exenatide (50ng/min for 30 minutes loading followed by 25ng/min maintenance) and glucagon 12.5ng/kg/min Sponsors:   Cambridge University Hospitals NHS Foundation Trust;   Antaros Medical AB Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials